A team led by Academician Ge Junbo and Professor Sun Aijun at Fudan University reveals that environmental eustress attenuates doxorubicin-induced cardiotoxicity while enhancing antitumor effects via a hypothalamus-heart-tumor axis. Eustress upregulates hypothalamic BDNF, which activates TrkB receptors on cardiac resident macrophages to inhibit CCL2 secretion, thereby reducing pro-inflammatory Ly6C^high monocyte/macrophage infiltration into heart tissue. In hepatocellular carcinoma models, eustress also downregulates tumor microenvironment CCL2, decreasing immunosuppressive G-MDSCs and M2 macrophages while increasing cytotoxic CD8+ T cells and M1 macrophages. CCL2 is identified as a core dual target for cardio-oncology intervention, providing a safe and accessible non-pharmacological strategy for preventing chemotherapy-related cardiac toxicity in cancer patients.

Prostate cancer (PCa) is a highly prevalent malignancy, heavily characterized by complex cellular heterogeneity and highly variable clinical outcomes. The Gleason score (GS) remains the fundamental histological grading system for evaluating tumor aggressiveness and predicting patient prognosis. However, the precise spatial dynamics and molecular transitions driving glandular epithelial (GE) cells from localized, low-grade lesions to highly advanced carcinomas have remained incompletely understood. 

A multi-omics study has revealed distinct extrachromosomal circular DNA (eccDNA) features associated with postoperative recurrence in lung adenocarcinoma (LUAD). 

Researchers from Keio University have found that D-serine increases the growth of gastric cancer by creating an immunosuppressive and anti-inflammatory tumor microenvironment. Higher levels of D-serine in serum correlated with greater immune checkpoint inhibitor therapy resistance in tumors. Suppressing D-serine in circulation could improve the efficacy of immunotherapies against gastric cancer. These findings position D-serine within the broader field of cancer amino acid metabolism and point to it as a possible target for tumor evasion.

Scientists at Sanford Burnham Prebys Medical Discovery Institute and their collaborators published findings August 7, 2026, in Science Advances showing that cancer cells’ cloaking costumes can be a result of changes in the nearby neighborhood of immune cells, connective tissue, blood vessels, proteins and carbohydrates called the tumor microenvironment. The researchers also found a way to thin this sugary shroud, enabling cancer cells to be recognized and eliminated by the immune system.

Researchers at MUSC Hollings Cancer Center and international collaborators have developed a new blood test that could help patients at high risk for lymphoma get to a biopsy and treatment sooner. The Access to Diagnosis using Liquid Biopsy (ADLiB) platform combines multiple genetic clues found in the blood with machine learning to estimate a patient’s likelihood of having lymphoma. In an initial study of 124 patients in South Africa, the platform correctly identified patients with lymphoma 95% of the time. Rather than replacing a tissue biopsy, researchers envision ADLiB as a tool to fast-track patients who need further testing, particularly in rural and resource-limited settings where access to specialized pathology expertise may be limited.

What does it take to bring lab-grade diagnostics into the home? New research from the University of Illinois has a practical answer: the VPodDuo, a fluorescence-testing device the size of an AirPods case, capable of detecting everything from HIV to cancer biomarkers.